2019 recipient: Dr Gabriela Brumatti
Dr Gabriela Brumatti, Walter and Eliza Hall Institute (WEHI), Melbourne.
Project title: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in acute myeloid leukaemia.
Acute myeloid leukaemia (AML) is an aggressive blood cancer, and the second most common form of leukaemia in children. Fewer than 30 per cent of AML patients can be cured with current therapies. This project will test a novel combination therapy, the Smac-mimetic drug birinapant plus multidrug resistance inhibitors (MDR1i), for the treatment of AML. This research will determine how this therapy can be effectively used to increase the chances of cure, with reduced side-effects for the patient’s benefit.Posted on February 5th, 2020
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.